NovoCure Limited
NVCR
$17.24
$0.392.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -0.17% | 4.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.17% | 4.27% | |||
| Cost of Revenue | -3.75% | -9.57% | |||
| Gross Profit | 0.91% | 9.33% | |||
| SG&A Expenses | 30.88% | 5.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.15% | 4.09% | |||
| Operating Income | -81.32% | -3.23% | |||
| Income Before Tax | -69.11% | -36.41% | |||
| Income Tax Expenses | 111.43% | -327.03% | |||
| Earnings from Continuing Operations | -190.37% | 34.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -190.37% | 34.27% | |||
| EBIT | -81.32% | -3.23% | |||
| EBITDA | -83.55% | -6.57% | |||
| EPS Basic | -185.48% | 34.44% | |||
| Normalized Basic EPS | -5.36% | -114.61% | |||
| EPS Diluted | -185.48% | 34.44% | |||
| Normalized Diluted EPS | -5.36% | -114.61% | |||
| Average Basic Shares Outstanding | 1.70% | 0.30% | |||
| Average Diluted Shares Outstanding | 1.70% | 0.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||